Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cannon

Showing results (371-380 of 1,137) with videos related to

Pageof 114
Sort By:
Journal of the American College of Cardiology|May 17, 2005
Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trialPaul M Ridker, David A Morrow, Lynda M Rose, et al.
Blood|November 24, 2001
Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromesF F O'Connor, D C Shields, A Fitzgerald, et al.
Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology|July 1, 1993
The encapsulation of squid diisopropylphosphorofluoridate-hydrolyzing enzyme within mouse erythrocytesW D McGuinn, E P Cannon, C T Chui, et al.
Journal of the American College of Cardiology|February 14, 1998
Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis in Myocardial Infarction (TIMI) 11A substudyE M Antman, D B Sacks, N Rifai, et al.
The American Journal of Cardiology|October 7, 1998
Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy. Thrombolysis In Myocardial InfarctionC P Cannon, W S Weintraub, L A Demopoulos, et al.
The American Journal of Cardiology|April 14, 2009
Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study)Patricia Tung, Stephen D Wiviott, Christopher P Cannon, et al.
Journal of the American College of Cardiology|August 21, 2012
The controversies of statin therapy: weighing the evidenceJ Wouter Jukema, Christopher P Cannon, Anton J M de Craen, et al.
Journal of the American College of Cardiology|December 5, 2009
Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) SubstudyC Michael Gibson, Yuri B Pride, Claudia P Hochberg, et al.
Circulation|May 9, 2002
Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarctionC Michael Gibson, Christopher P Cannon, Sabina A Murphy, et al.
The American Journal of Cardiology|June 30, 2015
On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study)Amit V Khera, Arman Qamar, Sabina A Murphy, et al.
Pageof 114

Showing results (371-380 of 1,137) with videos related to

Sort By:
Pageof 114
Journal of the American College of Cardiology|May 17, 2005
Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trialPaul M Ridker, David A Morrow, Lynda M Rose, et al.
Blood|November 24, 2001
Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromesF F O'Connor, D C Shields, A Fitzgerald, et al.
Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology|July 1, 1993
The encapsulation of squid diisopropylphosphorofluoridate-hydrolyzing enzyme within mouse erythrocytesW D McGuinn, E P Cannon, C T Chui, et al.
Journal of the American College of Cardiology|February 14, 1998
Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis in Myocardial Infarction (TIMI) 11A substudyE M Antman, D B Sacks, N Rifai, et al.
The American Journal of Cardiology|October 7, 1998
Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy. Thrombolysis In Myocardial InfarctionC P Cannon, W S Weintraub, L A Demopoulos, et al.
The American Journal of Cardiology|April 14, 2009
Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study)Patricia Tung, Stephen D Wiviott, Christopher P Cannon, et al.
Journal of the American College of Cardiology|August 21, 2012
The controversies of statin therapy: weighing the evidenceJ Wouter Jukema, Christopher P Cannon, Anton J M de Craen, et al.
Journal of the American College of Cardiology|December 5, 2009
Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) SubstudyC Michael Gibson, Yuri B Pride, Claudia P Hochberg, et al.
Circulation|May 9, 2002
Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarctionC Michael Gibson, Christopher P Cannon, Sabina A Murphy, et al.
The American Journal of Cardiology|June 30, 2015
On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study)Amit V Khera, Arman Qamar, Sabina A Murphy, et al.
Pageof 114